Mobocertinib

Takeda will work with the FDA toward voluntary withdrawal of its lung cancer therapy mobocertinib from the U.S. market, according to a company press release.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, discusses treatment variations for rarer mutations such as EGFR exon 20 insertions.

The FDA approved mobocertinib for treatment of certain patients with non-small cell lung cancer.

The FDA granted priority review to mobocertinib for treatment of certain patients with non-small cell lung cancer, according to the agent’s manufacturer.

The FDA granted breakthrough therapy designation to mobocertinib for treatment of certain patients with metastatic non-small cell lung cancer.